JP2017507131A5 - - Google Patents

Download PDF

Info

Publication number
JP2017507131A5
JP2017507131A5 JP2016550573A JP2016550573A JP2017507131A5 JP 2017507131 A5 JP2017507131 A5 JP 2017507131A5 JP 2016550573 A JP2016550573 A JP 2016550573A JP 2016550573 A JP2016550573 A JP 2016550573A JP 2017507131 A5 JP2017507131 A5 JP 2017507131A5
Authority
JP
Japan
Prior art keywords
antibody
seq
antibody agent
agent according
residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016550573A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017507131A (ja
JP6707455B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/015510 external-priority patent/WO2015123362A1/en
Publication of JP2017507131A publication Critical patent/JP2017507131A/ja
Publication of JP2017507131A5 publication Critical patent/JP2017507131A5/ja
Application granted granted Critical
Publication of JP6707455B2 publication Critical patent/JP6707455B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016550573A 2014-02-11 2015-02-11 新規フルスペクトル抗デング抗体 Active JP6707455B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461938605P 2014-02-11 2014-02-11
US61/938,605 2014-02-11
PCT/US2015/015510 WO2015123362A1 (en) 2014-02-11 2015-02-11 Novel full spectrum anti-dengue antibody

Publications (3)

Publication Number Publication Date
JP2017507131A JP2017507131A (ja) 2017-03-16
JP2017507131A5 true JP2017507131A5 (enExample) 2018-03-22
JP6707455B2 JP6707455B2 (ja) 2020-06-10

Family

ID=53800606

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016550573A Active JP6707455B2 (ja) 2014-02-11 2015-02-11 新規フルスペクトル抗デング抗体

Country Status (12)

Country Link
US (3) US9902764B2 (enExample)
EP (1) EP3104888A4 (enExample)
JP (1) JP6707455B2 (enExample)
KR (1) KR20160119806A (enExample)
CN (1) CN106413749B (enExample)
AU (1) AU2015217149B2 (enExample)
BR (1) BR112016017764A2 (enExample)
CA (1) CA2938495A1 (enExample)
IL (1) IL246788A0 (enExample)
MX (1) MX375402B (enExample)
SG (2) SG10201807826XA (enExample)
WO (1) WO2015123362A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102339457B1 (ko) 2007-09-26 2021-12-14 추가이 세이야쿠 가부시키가이샤 항체 정상영역 개변체
JP6297560B2 (ja) 2012-08-07 2018-03-20 マサチューセッツ インスティテュート オブ テクノロジー 抗デングウイルス抗体およびその使用
CN106413749B (zh) 2014-02-11 2022-04-05 麻省理工学院 新颖全谱抗登革抗体
AU2015217572B2 (en) * 2014-02-11 2020-10-15 Visterra, Inc. Antibody moleules to dengue virus and uses thereof
CN107108729A (zh) 2015-02-05 2017-08-29 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体,fc区变体,il‑8‑结合抗体,及其应用
CA3018216A1 (en) 2016-03-25 2017-09-28 Visterra, Inc. Formulations of antibody molecules to dengue virus
JP6527643B2 (ja) 2016-08-05 2019-06-05 中外製薬株式会社 Il−8関連疾患の治療用又は予防用組成物
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
JP2022008719A (ja) * 2016-11-23 2022-01-14 セルヴァス エーアイ インコーポレイテッド 疾患発症予測方法及び装置
DK3559027T3 (da) 2016-12-23 2022-09-05 Serum Institute Of India Pvt Ltd Fremgangsmåder til forbedring af antistofoproduktivitet i pattedyrecellekultur og minimering af aggregering nedstrøms, formuleringsprocesser og stabile antistofformuleringer opnået deraf
IL277375B2 (en) 2018-03-15 2025-08-01 Chugai Pharmaceutical Co Ltd Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
JPH049249A (ja) 1990-04-27 1992-01-14 Kusuda:Kk 塗型剤吹き付け機
DK0804070T3 (da) 1993-03-09 2000-08-07 Genzyme Corp Fremgangsmåde til isolering af proteiner fra mælk
US5500161A (en) 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
JPH07299655A (ja) 1994-04-30 1995-11-14 Aisin Seiki Co Ltd 内スプライン歯面仕上機
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
EP1430136A1 (en) 2001-09-27 2004-06-23 Pieris ProteoLab AG Muteins of apolipoprotein d
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
KR100708398B1 (ko) 2002-03-22 2007-04-18 (주) 에이프로젠 인간화 항체 및 이의 제조방법
US7232888B2 (en) 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens
US8409587B2 (en) 2002-11-01 2013-04-02 Glaxosmithkline Biologicals S.A. Immunogenic composition
CA2548808C (en) 2003-12-08 2015-07-07 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind or neutralize dengue virus
WO2006056464A2 (en) 2004-11-26 2006-06-01 Pieris Ag Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4)
WO2007021672A2 (en) 2005-08-10 2007-02-22 Acambis Inc. Vaccination against dengue virus infection
CU23586A1 (es) 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
CU23632A1 (es) 2006-04-28 2011-02-24 Ct Ingenieria Genetica Biotech Métodos para la identificación de candidatos terapéuticos contra enfermedades causadas por flavivirus y moléculas antivirales.
DK2257624T5 (da) 2008-02-05 2012-09-10 Medical Res Council Fremgangsmåder og sammensætninger
AU2008362482A1 (en) 2008-10-05 2010-04-08 The Board Of Trustees Of The Leland Stanford Junior University Hepatitis C antibodies and uses thereof
JP5814790B2 (ja) * 2008-10-13 2015-11-17 インスティテュート・フォー・リサーチ・イン・バイオメディシンInstitute For Research In Biomedicine デングウイルス中和抗体およびその使用
CN102573905A (zh) 2008-12-05 2012-07-11 勒帕斯公司 利用抗脂类抗体晶体结构的抗体设计
SG173482A1 (en) 2009-02-10 2011-09-29 Univ Nanyang Tech Antibodies for diagnosis and treatment of flaviviral infections
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
US8637035B2 (en) * 2010-07-16 2014-01-28 Academia Sinica Anti-dengue virus antibodies
US20140349321A1 (en) 2011-12-16 2014-11-27 Agency For Science, Technology And Research Binding molecules against dengue virus and uses thereof
US9556254B2 (en) 2012-05-14 2017-01-31 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Cross-reactive antibodies against dengue virus and uses thereof
JP6297560B2 (ja) 2012-08-07 2018-03-20 マサチューセッツ インスティテュート オブ テクノロジー 抗デングウイルス抗体およびその使用
AU2015217572B2 (en) 2014-02-11 2020-10-15 Visterra, Inc. Antibody moleules to dengue virus and uses thereof
CN106413749B (zh) 2014-02-11 2022-04-05 麻省理工学院 新颖全谱抗登革抗体

Similar Documents

Publication Publication Date Title
JP2017507131A5 (enExample)
JP2020522261A5 (enExample)
JP2016529882A5 (enExample)
JP2017501711A5 (enExample)
RU2015136078A (ru) Антитело против с5 и способ предупреждения и лечения обусловленных комплементом заболеваний
JP2015503909A5 (enExample)
JP2015525795A5 (enExample)
JP2011509245A5 (enExample)
US20200347130A1 (en) CD96 Antibody, Antigen-Binding Fragment and Pharmaceutical use Thereof
JP2018502060A5 (enExample)
IL261666B1 (en) Binding proteins and methods of use thereof
JP2018508188A5 (enExample)
JP2013502913A5 (enExample)
JP2010536384A5 (enExample)
JP2017505121A5 (enExample)
JP2014534806A5 (enExample)
RU2016100892A (ru) Антитела против tweakr и их применение
RU2018129874A (ru) Антитела против фактора свертывания xi
JP2019505527A5 (enExample)
JP2005528914A5 (enExample)
JP2017537082A5 (enExample)
US12173081B2 (en) CD19/CD38 multispecific antibodies
JP2013508292A5 (enExample)
JP2020515277A5 (enExample)
JP2016501877A5 (enExample)